Georg Nebgen
Director/Board Member at Kika Medical International Co.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Nicolas Dubost | M | - |
Kika Medical International Co.
Kika Medical International Co. Packaged SoftwareTechnology Services KIKA helps the world's most innovative biopharmaceutical and medical device organizations use advanced EDC solutions to bring much-needed medical solutions to market faster. KIKA's Veracity™ is the leading-edge Web-based clinical trial software platform that delivers Clinical Asset Management™ for any size clinical trial. Veracity is customized to meet study needs precisely. It provides unmatched flexibility and customization with advanced EDC including images and online adjudication. Veracity is backed by the industry's most reliable IT infrastructure and a world class Professional Services organization | 22 years |
Jean Paul Ortelli | M | - |
Kika Medical International Co.
Kika Medical International Co. Packaged SoftwareTechnology Services KIKA helps the world's most innovative biopharmaceutical and medical device organizations use advanced EDC solutions to bring much-needed medical solutions to market faster. KIKA's Veracity™ is the leading-edge Web-based clinical trial software platform that delivers Clinical Asset Management™ for any size clinical trial. Veracity is customized to meet study needs precisely. It provides unmatched flexibility and customization with advanced EDC including images and online adjudication. Veracity is backed by the industry's most reliable IT infrastructure and a world class Professional Services organization | - |
Benoît S. Lopez | M | - |
Kika Medical International Co.
Kika Medical International Co. Packaged SoftwareTechnology Services KIKA helps the world's most innovative biopharmaceutical and medical device organizations use advanced EDC solutions to bring much-needed medical solutions to market faster. KIKA's Veracity™ is the leading-edge Web-based clinical trial software platform that delivers Clinical Asset Management™ for any size clinical trial. Veracity is customized to meet study needs precisely. It provides unmatched flexibility and customization with advanced EDC including images and online adjudication. Veracity is backed by the industry's most reliable IT infrastructure and a world class Professional Services organization | - |
William Gedale | M | 81 |
Kika Medical International Co.
Kika Medical International Co. Packaged SoftwareTechnology Services KIKA helps the world's most innovative biopharmaceutical and medical device organizations use advanced EDC solutions to bring much-needed medical solutions to market faster. KIKA's Veracity™ is the leading-edge Web-based clinical trial software platform that delivers Clinical Asset Management™ for any size clinical trial. Veracity is customized to meet study needs precisely. It provides unmatched flexibility and customization with advanced EDC including images and online adjudication. Veracity is backed by the industry's most reliable IT infrastructure and a world class Professional Services organization | - |
Eric Archambeau | M | 66 |
Kika Medical International Co.
Kika Medical International Co. Packaged SoftwareTechnology Services KIKA helps the world's most innovative biopharmaceutical and medical device organizations use advanced EDC solutions to bring much-needed medical solutions to market faster. KIKA's Veracity™ is the leading-edge Web-based clinical trial software platform that delivers Clinical Asset Management™ for any size clinical trial. Veracity is customized to meet study needs precisely. It provides unmatched flexibility and customization with advanced EDC including images and online adjudication. Veracity is backed by the industry's most reliable IT infrastructure and a world class Professional Services organization | - |
Linda Beneze | F | - |
Kika Medical International Co.
Kika Medical International Co. Packaged SoftwareTechnology Services KIKA helps the world's most innovative biopharmaceutical and medical device organizations use advanced EDC solutions to bring much-needed medical solutions to market faster. KIKA's Veracity™ is the leading-edge Web-based clinical trial software platform that delivers Clinical Asset Management™ for any size clinical trial. Veracity is customized to meet study needs precisely. It provides unmatched flexibility and customization with advanced EDC including images and online adjudication. Veracity is backed by the industry's most reliable IT infrastructure and a world class Professional Services organization | 16 years |
Frédéric Durand-Salmon | M | - |
Kika Medical International Co.
Kika Medical International Co. Packaged SoftwareTechnology Services KIKA helps the world's most innovative biopharmaceutical and medical device organizations use advanced EDC solutions to bring much-needed medical solutions to market faster. KIKA's Veracity™ is the leading-edge Web-based clinical trial software platform that delivers Clinical Asset Management™ for any size clinical trial. Veracity is customized to meet study needs precisely. It provides unmatched flexibility and customization with advanced EDC including images and online adjudication. Veracity is backed by the industry's most reliable IT infrastructure and a world class Professional Services organization | 27 years |
Alexandre Durand-Salmon | M | - |
Kika Medical International Co.
Kika Medical International Co. Packaged SoftwareTechnology Services KIKA helps the world's most innovative biopharmaceutical and medical device organizations use advanced EDC solutions to bring much-needed medical solutions to market faster. KIKA's Veracity™ is the leading-edge Web-based clinical trial software platform that delivers Clinical Asset Management™ for any size clinical trial. Veracity is customized to meet study needs precisely. It provides unmatched flexibility and customization with advanced EDC including images and online adjudication. Veracity is backed by the industry's most reliable IT infrastructure and a world class Professional Services organization | 27 years |
Kristine Klinger | F | - |
Kika Medical International Co.
Kika Medical International Co. Packaged SoftwareTechnology Services KIKA helps the world's most innovative biopharmaceutical and medical device organizations use advanced EDC solutions to bring much-needed medical solutions to market faster. KIKA's Veracity™ is the leading-edge Web-based clinical trial software platform that delivers Clinical Asset Management™ for any size clinical trial. Veracity is customized to meet study needs precisely. It provides unmatched flexibility and customization with advanced EDC including images and online adjudication. Veracity is backed by the industry's most reliable IT infrastructure and a world class Professional Services organization | 16 years |
Brenda Nashawaty | F | - |
Kika Medical International Co.
Kika Medical International Co. Packaged SoftwareTechnology Services KIKA helps the world's most innovative biopharmaceutical and medical device organizations use advanced EDC solutions to bring much-needed medical solutions to market faster. KIKA's Veracity™ is the leading-edge Web-based clinical trial software platform that delivers Clinical Asset Management™ for any size clinical trial. Veracity is customized to meet study needs precisely. It provides unmatched flexibility and customization with advanced EDC including images and online adjudication. Veracity is backed by the industry's most reliable IT infrastructure and a world class Professional Services organization | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Fred H. Mermelstein | M | 64 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 12 years |
Stephen Tulipano | M | 65 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 4 years |
Martin Driscoll | M | 65 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 2 years |
Jackie Marie Clegg | F | 62 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 6 years |
David B. Bernstein | M | 61 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | - |
Douglas G. Watson | M | 79 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 9 years |
Neil William Flanzraich | M | 80 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 4 years |
Peter Morgan Kash | M | 62 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | - |
Pepyn René Dinandt | M | 62 |
Mannesmann Plastics Machinery GmbH
Mannesmann Plastics Machinery GmbH Industrial MachineryProducer Manufacturing Mannesmann Plastics Machinery GmbH manufactures plastics and rubber processing machines. It operates in three business divisions: Injection Moulding Technology, Reaction Technology, and Extrusion Technology. The firm offers extruders to produce TPE, silicone, rubber, and hybrid profiles, including extrusion, vulcanisation, and downstream equipment. The company was founded in 1998 and is headquartered in Munich, Germany. | 4 years |
Peter D. Kiernan | M | 70 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 4 years |
Susan J. Schniepp | F | - |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | - |
Eric Lang | M | - |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | - |
John Taylor | M | 54 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 22 | 95.65% |
Germany | 1 | 4.35% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Georg Nebgen
- Personal Network